Figure 2 | Translational Psychiatry

Figure 2

From: Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin–proteasome systems

Figure 2

Chronic paroxetine treatment resulted in differential expression of glutamatergic pathway proteins between PLF and PSF groups. (a) NMDAR subunits and signalling protein and phosphorylation levels among the groups. The NMDAR subunit proteins were blotted using membrane-associated fraction. The NMDAR signalling proteins were blotted using cytoplasm-associated fraction, n=5 per group. (b) Glutamate metabolism and synapse/vesicle trafficking pathway protein level differences among the groups, n=5 per group. The proteins were blotted using cytoplasm-associated fraction. Data are expressed as the mean±s.e.m. *P<0.05, **P<0.01, ***P<0.001 vs VIF, #P<0.05, ##P<0.01, ###P<0.001 vs PLF (one-way analysis of variance (ANOVA) with Tukey’s test). Coomassie brilliant blue staining was used as a loading control. The VIF mice were selected as a control group. NMDAR, N-methyl-d-aspartate receptor; PLF, paroxetine-treated long-time floating; PSF, paroxetine-treated short-time floating; SYNJ1, synaptojanin 1; VIF, vehicle-treated intermediate-time floating.

Back to article page